Preclinical data have shown that SLC-0111, a CAIX inhibitor, acts synergistically with immune checkpoint inhibitors such as anti-PD1 or anti-CTLA4 to suppress tumor vascularization and metastasis in a TNBC xenograft model [309, 310]. Here, CA9 is linked to neoplasm.